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Material and Methods: Synthetic CT images (sCT) were generated using the Statistical Decomposition Algorithm (SDA, MriPlanner, Spectronic Medical AB, Sweden). The algorithm uses a T2-weighted MRI for sCT generation, based on a multi-template assisted classification method. In order to exclude the effect of geometrical distortions and patient deformation owing to reposition between imaging sessions, a registered CT (rCT) was constructed by deformable registration with the MR using the Elastix toolbox.
Five-field IMRT plans (both 6 and 10 MV) were created for six patients, using the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, CA). Final dose calculations were made using the anisotropic analytical algorithm (AAA). The rCT was used for the initial treatment planning and the plan was recalculated on the sCT. Thus, the two treatment plans created for each patient had the same number of monitor units for each field. The resulting dose distributions from the rCT-and sCT-treatment plans were compared based on a set of dose volume histogram criteria according, and by using gamma evaluation. The reliability of the MRI-based fiducial marker identification was evaluated by an observer study. For this part of the study, the position of gold fiducial markers were determined by six independent observers using an MRI sequence dedicated for marker identification (LAVA-flex). Each marker position, three for each patient, were compared between the observers. The observers graded (one to five, were five represents the highest level of confidence) their confidence by which the markers for each patient were identified.
Results:
The mean dose differences to PTV between plans based on sCT and rCT were -0.1%±0.3% (1 s.d) (6MV) and -0.2%±0.2% (1 s.d) (10 MV). Gamma analysis showed pass rates ranging between 98% and 100% for both energies, with gamma criteria of 1%/2mm (local dose deviation). The mean standard deviation of the marker position, as determined by the observers, was 0.6 mm in all directions (x, y and z). One marker identification result was excluded due to an incorrect identification by one observer. The confidence grading ranged between 2 and 5.
Conclusion:
This work demonstrates that SDA can provide sufficient dosimetric accuracy for an MRI only workflow for prostate cancer patients. However, gold fiducials cannot be identified using LAVA-flex with high enough confidence and further work is needed to develop methods for marker identification in an MRI only workflow.
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Prostate fiducial markers detection with the use of multiparametric-MRI C.D. Fernandes Purpose or Objective: Prostate cancer patients scheduled for EBRT are often implanted with fiducial markers for position verification. A precondition for an MR-only workflow is the possibility to identify them on MRI. The markers present as signal voids in most images and their apparent position depends on their shape and orientation relative to the magnetic field. Rather than acquiring a sequence for this single purpose, we propose to use a model for the automatic detection of fiducial markers combining information from the entire multiparametric (mp) MRI protocol used for target delineation.
Material and Methods: Thirty prostate cancer patients scheduled for EBRT were implanted with 2-3 gold fiducial markers (0.9x3mm). A mp-MRI (T1w, T2w, B0-mapping and mDIXON) was performed using a 3T MRI (Achieva, Philips) and a CT with a 24-slice CT scanner (Somatom-Sensation-Open, Siemens).The reference position of the markers was based on the segmented CT images. The MRI was registered to the CT and resampled to the grid of 0.9x0.9x3mm3. A logistic regression model was developed to estimate the location of the markers based on the following MRI features: signal intensity, mean, median, min, max and standard deviation values in a kernel of 3x3x3vox and a multi-scale blobness filter [1] of the prostate region. The model was crossvalidated using a leave-one-out method. Performance was assessed using features from each separate imaging sequence and by combining the features from all sequences. Voxels detected as markers by the model were grouped into clusters. We defined the probability of each cluster candidate as the highest probability value of all voxels within it. Results were further post-processed by selecting the n(i) highest probability clusters, where n(i) is the number of markers implanted in patient i. Results were classified as a false positive (FP) if the distance between the reference
